| |
| |
|
| Insider
Information: |
Francomano Robert |
| Relationship: |
Chief Commercial Officer |
| City: |
New York |
| State: |
NY |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
40,918 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$50,738 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
40,918 |
|
|
| Total
Value |
$50,738 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
|
|
| Stock
price went down : |
|
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Stemline Therapeutics Inc |
STML |
Chief Commercial Officer |
2020-06-10 |
0 |
|
0 |
Premium* |
|
|
SELLAS Life Sciences Group Inc |
SLS |
Chief Commercial Officer |
2024-01-22 |
40,918 |
2023-02-02 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
13 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| SLS |
SELLAS Life Sciences Grou... |
Chief Commercial Officer |
• – – |
2024-01-22 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
40,918 |
0 |
- |
|
| SLS |
SELLAS Life Sciences Grou... |
Chief Commercial Officer |
• – – |
2023-12-06 |
4 |
D |
$1.08 |
$1,169 |
D/D |
(1,082) |
20,918 |
0 |
- |
|
| SLS |
SELLAS Life Sciences Grou... |
Chief Commercial Officer |
• – – |
2023-02-02 |
4 |
A |
$0.00 |
$0 |
D/D |
12,000 |
12,000 |
0 |
- |
|
| STML |
Stemline Therapeutics Inc |
Chief Commercial Officer |
• – – |
2020-06-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(200,891) |
0 |
0 |
- |
|
| STML |
Stemline Therapeutics Inc |
Chief Commercial Officer |
• – – |
2020-05-04 |
4 |
S |
$11.51 |
$3,131 |
D/D |
(272) |
197,658 |
0 |
% |
|
| STML |
Stemline Therapeutics Inc |
Chief Commercial Officer |
• – – |
2020-03-09 |
4 |
S |
$5.00 |
$6,330 |
D/D |
(1,266) |
197,930 |
0 |
% |
|
| STML |
Stemline Therapeutics Inc |
Chief Commercial Officer |
• – – |
2020-02-10 |
4 |
A |
$0.00 |
$0 |
D/D |
105,939 |
199,196 |
0 |
- |
|
| STML |
Stemline Therapeutics Inc |
Chief Commercial Officer |
• – – |
2020-02-07 |
4 |
S |
$6.72 |
$34,030 |
D/D |
(5,064) |
93,257 |
0 |
% |
|
| STML |
Stemline Therapeutics Inc |
Chief Commercial Officer |
• – – |
2019-12-27 |
4 |
S |
$10.48 |
$1,216 |
D/D |
(116) |
98,321 |
0 |
- |
|
| STML |
Stemline Therapeutics Inc |
Chief Commercial Officer |
• – – |
2019-12-26 |
4 |
S |
$10.75 |
$9,600 |
D/D |
(893) |
98,437 |
0 |
- |
|
| STML |
Stemline Therapeutics Inc |
Chief Commercial Officer |
• – – |
2019-12-24 |
4 |
S |
$10.97 |
$15,490 |
D/D |
(1,412) |
99,330 |
0 |
- |
|
| STML |
Stemline Therapeutics Inc |
Chief Commercial Officer |
• – – |
2019-12-23 |
4 |
S |
$10.58 |
$2,634 |
D/D |
(249) |
100,742 |
0 |
- |
|
| STML |
Stemline Therapeutics Inc |
Chief Commercial OfficerOffice |
• – – |
2019-12-06 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
100,991 |
|
- |
|
13 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
